04:10 AM EST, 01/27/2025 (MT Newswires) -- Innate Pharma SA ( IPHA ) said Monday it has dosed its first patient in a phase 1 study to investigate the safety and tolerability of IPH4502, an antibody-drug conjugate for the potential treatment of patients with advanced solid tumors known to express Nectin-4.

IPH4502 is designed to target Nectin-4, a cell adhesion molecule in several types of solid tumors, including urothelial carcinoma, breast cancer, non-small cell lung cancer, and gastrointestinal cancer, the company said.

The study plans to enroll about 105 patients, the company said.